AU2015236008B2 - Methods of preparing a poloxamer for use in cell culture medium - Google Patents

Methods of preparing a poloxamer for use in cell culture medium Download PDF

Info

Publication number
AU2015236008B2
AU2015236008B2 AU2015236008A AU2015236008A AU2015236008B2 AU 2015236008 B2 AU2015236008 B2 AU 2015236008B2 AU 2015236008 A AU2015236008 A AU 2015236008A AU 2015236008 A AU2015236008 A AU 2015236008A AU 2015236008 B2 AU2015236008 B2 AU 2015236008B2
Authority
AU
Australia
Prior art keywords
poloxamer
minutes
cell
cell culture
heated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015236008A
Other languages
English (en)
Other versions
AU2015236008A1 (en
Inventor
Amelia ADAMS
Kara Calhoun
Alan Deese
Marion GLENN
Robert David Kiss
Stefan Koenig
Inchan Kwon
Steven J. Meier
Ganesh Prasadh Vissvesvaran
Kate WINCHESTER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2015236008A1 publication Critical patent/AU2015236008A1/en
Application granted granted Critical
Publication of AU2015236008B2 publication Critical patent/AU2015236008B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/30—Post-polymerisation treatment, e.g. recovery, purification, drying
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/50—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing nitrogen, e.g. polyetheramines or Jeffamines(r)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/58—Ethylene oxide or propylene oxide copolymers, e.g. pluronics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/50—Soluble polymers, e.g. polyethyleneglycol [PEG]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2015236008A 2014-03-25 2015-03-25 Methods of preparing a poloxamer for use in cell culture medium Active AU2015236008B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970281P 2014-03-25 2014-03-25
US61/970,281 2014-03-25
PCT/US2015/022592 WO2015148736A1 (en) 2014-03-25 2015-03-25 Methods of preparing a poloxamer for use in cell culture medium

Publications (2)

Publication Number Publication Date
AU2015236008A1 AU2015236008A1 (en) 2016-10-27
AU2015236008B2 true AU2015236008B2 (en) 2018-12-20

Family

ID=52824596

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015236008A Active AU2015236008B2 (en) 2014-03-25 2015-03-25 Methods of preparing a poloxamer for use in cell culture medium

Country Status (19)

Country Link
US (2) US11034793B2 (enExample)
EP (2) EP3778702B1 (enExample)
JP (3) JP6655548B2 (enExample)
KR (1) KR102352250B1 (enExample)
CN (2) CN111808276A (enExample)
AU (1) AU2015236008B2 (enExample)
BR (1) BR112016021739B1 (enExample)
CA (1) CA2943357C (enExample)
ES (1) ES2778680T3 (enExample)
HR (1) HRP20200372T1 (enExample)
IL (2) IL247902B (enExample)
MX (2) MX2016012288A (enExample)
MY (1) MY178060A (enExample)
PL (1) PL3122799T3 (enExample)
RU (1) RU2710551C2 (enExample)
SG (1) SG11201607929PA (enExample)
SI (1) SI3122799T1 (enExample)
WO (1) WO2015148736A1 (enExample)
ZA (1) ZA201606711B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3778702B1 (en) 2014-03-25 2023-06-28 F. Hoffmann-La Roche AG Methods of preparing a poloxamer for use in cell culture medium
EP3430072B1 (en) * 2016-03-17 2020-07-01 Merck Patent GmbH Method for purifying poloxamers
KR102662905B1 (ko) * 2017-12-21 2024-05-03 시그마-알드리치 컴퍼니., 엘엘씨 폴록사머 조성물 및 이의 제조 및 사용 방법
RU2741710C1 (ru) * 2018-07-12 2021-01-28 Елена Валентиновна Аршинцева Термический способ стерилизации жидких лекарственных средств, содержащих в своем составе полоксамер
EP3831932A4 (en) * 2018-07-27 2021-09-15 Ajinomoto Co., Inc. SUSPENSION CULTURE ADDITIVE, SUSPENSION CULTURE MEDIA AND SUSPENSION CULTURE METHOD FOR ANIMAL CELLS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071452A2 (en) * 2003-02-12 2004-08-26 Ceremed, Inc. Random and non-random alkylene oxide polymer alloy compositions
EP1661558B1 (en) * 2004-11-30 2010-07-21 Basf Se Compositions based on micro-prilled poloxamer particles and methods for their manufacturing

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (enExample)
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
AU2699892A (en) * 1991-10-04 1993-05-03 Gs Biochem Ab Particles, method of preparing said particles and uses thereof
DE69527195T2 (de) 1994-01-14 2003-03-06 Xoma Technology Ltd., Berkeley Anti gram positive bakterielle verfahren und mittel
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
GB9625175D0 (en) * 1996-12-04 1997-01-22 Medi Cult As Serum-free cell culture media
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU2003900887A0 (en) * 2003-02-27 2003-03-13 Novasel Australia Pty Ltd Poloxamer emulsion preparations
US8802116B2 (en) * 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
JP5180474B2 (ja) * 2003-08-04 2013-04-10 カムルス エービー 両親媒性粒子の特性を改良する方法
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US20060121016A1 (en) 2004-10-18 2006-06-08 Lee Raphael C Methods and compositions for treatment of free radical injury
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
KR100932613B1 (ko) * 2007-04-27 2009-12-17 한남대학교 산학협력단 고분자 용융공정을 이용한 약물전달용 생체적합성 고분자나노 미립구의 제조방법 및 그 나노 미립구
WO2009055312A1 (en) * 2007-10-22 2009-04-30 Dfb Pharmaceuticals, Inc. Process for producing a poloxamer gel
PL2235197T3 (pl) 2007-12-27 2018-01-31 Baxalta GmbH Sposoby hodowli komórek
AU2010334723C1 (en) * 2009-12-23 2015-05-28 Sanofi Pasteur Method for culturing adherent cells
US9629811B2 (en) * 2012-03-30 2017-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsphere compositions, preparation method and applications thereof
EP3778702B1 (en) * 2014-03-25 2023-06-28 F. Hoffmann-La Roche AG Methods of preparing a poloxamer for use in cell culture medium

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071452A2 (en) * 2003-02-12 2004-08-26 Ceremed, Inc. Random and non-random alkylene oxide polymer alloy compositions
EP1661558B1 (en) * 2004-11-30 2010-07-21 Basf Se Compositions based on micro-prilled poloxamer particles and methods for their manufacturing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YONG C S ET AL, "Enhanced anti-tumor activity and alleviated hepatotoxicity of clotrimazole-loaded suppository using poloxamer-propylene glycol gel", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 321, no. 1-2, 2006-09-14, p 56 - 61 *

Also Published As

Publication number Publication date
NZ725151A (en) 2021-05-28
HRP20200372T1 (hr) 2020-06-12
BR112016021739B1 (pt) 2021-11-03
IL247902B (en) 2021-01-31
EP3122799A1 (en) 2017-02-01
IL279583A (en) 2021-03-01
JP7472222B2 (ja) 2024-04-22
ES2778680T3 (es) 2020-08-11
MX2021001981A (es) 2021-04-28
KR20160138161A (ko) 2016-12-02
JP2023011566A (ja) 2023-01-24
EP3778702A1 (en) 2021-02-17
CN111808276A (zh) 2020-10-23
MX2016012288A (es) 2017-01-23
RU2016141568A (ru) 2018-04-28
IL279583B (en) 2022-03-01
US20210371587A1 (en) 2021-12-02
PL3122799T3 (pl) 2020-06-29
AU2015236008A1 (en) 2016-10-27
BR112016021739A2 (pt) 2017-08-15
SG11201607929PA (en) 2016-10-28
ZA201606711B (en) 2019-12-18
JP2017516459A (ja) 2017-06-22
RU2016141568A3 (enExample) 2018-09-26
KR102352250B1 (ko) 2022-01-17
US11034793B2 (en) 2021-06-15
CN106414552A (zh) 2017-02-15
US20170009015A1 (en) 2017-01-12
CN106414552B (zh) 2020-08-25
CA2943357C (en) 2023-06-27
US11912823B2 (en) 2024-02-27
MY178060A (en) 2020-09-30
RU2710551C2 (ru) 2019-12-27
JP6655548B2 (ja) 2020-02-26
JP2020103290A (ja) 2020-07-09
CA2943357A1 (en) 2015-10-01
IL247902A0 (en) 2016-11-30
EP3778702B1 (en) 2023-06-28
WO2015148736A8 (en) 2016-08-18
EP3122799B8 (en) 2020-03-11
SI3122799T1 (sl) 2020-06-30
EP3122799B1 (en) 2020-01-15
WO2015148736A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
US11912823B2 (en) Methods of preparing a poloxamer for use in cell culture medium
JP7377316B2 (ja) 哺乳類細胞培養物を回収するための方法
US20230159974A1 (en) Process for manipulating the level of glycan content of a glycoprotein
JP2022036940A (ja) 環境適合性洗浄剤を使用するウイルス不活性化方法
NZ725151B2 (en) Methods of preparing a poloxamer for use in cell culture medium
HK40038241A (en) Methods of preparing a poloxamer for use in cell culture medium
HK1233287A1 (en) Methods of preparing a poloxamer for use in cell culture medium
HK1233287B (zh) 制备用於细胞培养基中的泊洛沙姆的方法
HK40008326A (en) Method and system for providing buffer solutions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)